These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 16438854

  • 21. Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19.
    Murtezaoglu AR, Gucer H.
    Pol J Pathol; 2017; 68(1):1-10. PubMed ID: 28547974
    [Abstract] [Full Text] [Related]

  • 22. Low Elasticity of Thyroid Nodules on Ultrasound Elastography Is Correlated with Malignancy, Degree of Fibrosis, and High Expression of Galectin-3 and Fibronectin-1.
    Rago T, Scutari M, Loiacono V, Santini F, Tonacchera M, Torregrossa L, Giannini R, Borrelli N, Proietti A, Basolo F, Miccoli P, Piaggi P, Latrofa F, Vitti P.
    Thyroid; 2017 Jan; 27(1):103-110. PubMed ID: 27809694
    [Abstract] [Full Text] [Related]

  • 23. Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease.
    Saussez S, Glinoer D, Chantrain G, Pattou F, Carnaille B, André S, Gabius HJ, Laurent G.
    Thyroid; 2008 Jul; 18(7):705-12. PubMed ID: 18630998
    [Abstract] [Full Text] [Related]

  • 24. Usefulness of cytokeratin-19, galectin-3, and Hector Battifora mesothelial-1 in the diagnosis of benign and malignant thyroid nodules.
    Cui W, Sang W, Zheng S, Ma Y, Liu X, Zhang W.
    Clin Lab; 2012 Jul; 58(7-8):673-80. PubMed ID: 22997967
    [Abstract] [Full Text] [Related]

  • 25. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.
    Park YJ, Kwak SH, Kim DC, Kim H, Choe G, Park DJ, Jang HC, Park SH, Cho BY, Park SY.
    J Korean Med Sci; 2007 Aug; 22(4):621-8. PubMed ID: 17728499
    [Abstract] [Full Text] [Related]

  • 26. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma.
    Jakubiak-Wielganowicz M, Kubiak R, Sygut J, Pomorski L, Kordek R.
    Pol J Pathol; 2003 Aug; 54(2):111-5. PubMed ID: 14575419
    [Abstract] [Full Text] [Related]

  • 27. Intensity and distribution of immunohistochemical expression of galectin-3 in thyroid neoplasms.
    Matesa-Anić D, Moslavac S, Matesa N, Cupić H, Kusić Z.
    Acta Clin Croat; 2012 Jun; 51(2):237-41. PubMed ID: 23115948
    [Abstract] [Full Text] [Related]

  • 28. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
    Mehrotra P, Okpokam A, Bouhaidar R, Johnson SJ, Wilson JA, Davies BR, Lennard TW.
    Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
    [Abstract] [Full Text] [Related]

  • 29. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications.
    Xu XC, el-Naggar AK, Lotan R.
    Am J Pathol; 1995 Sep; 147(3):815-22. PubMed ID: 7677193
    [Abstract] [Full Text] [Related]

  • 30. Quantitative Analysis of Galectin-3 Expression in Benign and Malignant Thyroid Nodules.
    Šamija I, Mateša N, Tadinac S, Jukić T.
    Acta Clin Croat; 2020 Jun; 59(Suppl 1):25-31. PubMed ID: 34219881
    [Abstract] [Full Text] [Related]

  • 31. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study.
    Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, Palestini N, Ghigo E, Papotti M, Bussolati G, Martegani MP, Pantellini F, Carpi A, Giovagnoli MR, Monti S, Toscano V, Sciacchitano S, Pennelli GM, Mian C, Pelizzo MR, Rugge M, Troncone G, Palombini L, Chiappetta G, Botti G, Vecchione A, Bellocco R, Italian Thyroid Cancer Study Group (ITCSG).
    Lancet Oncol; 2008 Jun; 9(6):543-9. PubMed ID: 18495537
    [Abstract] [Full Text] [Related]

  • 32. Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia.
    Coli A, Bigotti G, Zucchetti F, Negro F, Massi G.
    Histopathology; 2002 Jan; 40(1):80-7. PubMed ID: 11903601
    [Abstract] [Full Text] [Related]

  • 33. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
    Than TH, Swethadri GK, Wong J, Ahmad T, Jamil D, Maganlal RK, Hamdi MM, Abdullah MS.
    Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
    [Abstract] [Full Text] [Related]

  • 34. [Expression of cell adhesion molecule (CD44V6) in thyroid tumors and its significance].
    Li L, Lin L, Qiu J.
    Zhonghua Nei Ke Za Zhi; 2001 Oct; 40(10):677-80. PubMed ID: 11769722
    [Abstract] [Full Text] [Related]

  • 35. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules.
    Beesley MF, McLaren KM.
    Histopathology; 2002 Sep; 41(3):236-43. PubMed ID: 12207785
    [Abstract] [Full Text] [Related]

  • 36. Differential expression of galectin-3 in papillary projections of malignant and non-malignant hyperplastic thyroid lesions.
    Cvejić D, Savin S, Petrović I, Paunović I, Tatić S, Havelka M.
    Acta Chir Iugosl; 2003 Sep; 50(3):67-70. PubMed ID: 15179758
    [Abstract] [Full Text] [Related]

  • 37. [Low galectin-3 capacity to discriminate thyroid lesions].
    De-León-Mazariegos R, Canedo-Patzi M, Pérez-Enríquez B, Candanedo-Gonzalez F, Saqui-Salces M, Gamboa-Domínguez A, Rull-Rodrigo JA.
    Rev Invest Clin; 2004 Sep; 56(5):623-8. PubMed ID: 15776867
    [Abstract] [Full Text] [Related]

  • 38. Expression and significance of IGF-1 and IGF-1R in thyroid nodules.
    Liu YJ, Qiang W, Shi J, Lv SQ, Ji MJ, Shi BY.
    Endocrine; 2013 Aug; 44(1):158-64. PubMed ID: 23288662
    [Abstract] [Full Text] [Related]

  • 39. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
    He CN, He L, Cheng JQ, Chen SC, Zhao HF, Zhai JP, Zhang J.
    Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983
    [Abstract] [Full Text] [Related]

  • 40. An antibody-like peptide that recognizes malignancy among thyroid nodules.
    Reis CF, Carneiro AP, Vieira CU, Fujimura PT, Morari EC, Silva SJ, Goulart LR, Ward LS.
    Cancer Lett; 2013 Jul 28; 335(2):306-13. PubMed ID: 23462224
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.